Darlene Deptula-Hicks

Ms. Deptula-Hicks is recognized for her breadth of expertise in growth strategies and success at capital raising and initial public offerings (IPO). She currently serves as the Chief Financial Officer of Verseau Therapeutics and F-star Therapeutics, Inc. (NASDAQ: FSTX) which she took public in 2020 and raised approximately $100M in equity financings. She provides strategic financial and business direction and leadership on long-term strategies and decisions affecting the future financial performance of these organizations including capital formation, commercialization, strategy, and M&A. Previously, she was Chief Financial Officer of Northern Biologics and T2 Biosystems, Inc. (NASDAQ: TTOO). She also served as Senior Vice President and Chief Financial Officer, and Secretary of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS). Within that role, she took Pieri's public and was responsible for financial strategy development and capital formation, leading the company in three rounds of public equity financing and closing several significant strategic collaborations.